search icon

      Market Snapshot

      blog search icon

      Here’s Why You Should Avoid iBio (IBIO) Stocks For COVID-19 Vaccine

      By Hasnain R

      Published on

      September 18, 2020

      12:35 PM UTC

      Here’s Why You Should Avoid iBio (IBIO) Stocks For COVID-19 Vaccine

      All the companies involved in the production of the coronavirus vaccine, iBio is far behind from its competitors in the vaccine trial. The company has earlier revealed that it has selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate for the prevention of coronavirus infection. But the company has not provided any promising result related to its coronavirus vaccine candidate nor it entered into the human trial of its vaccine candidate.

      iBio, a biotech innovator and biologics contract manufacturing organization has earlier made the various claims about its vaccine candidate. It has claimed exclusive worldwide license agreement on a cure called ACE2-Fc from Planet  Biotechnology. Not only this, but the company also claimed that its FastPharming system has the ability to produce vaccines quickly using plant cells.

      So, it is better to avoid iBio for the coronavirus vaccine until it catches up and moves its coronavirus vaccine candidate into human trials. Many companies including Moderna, Novavax, AstraZeneca, and Pfizer all are currently in human trials of their vaccine candidate. But iBio, Inc. is still in the lab and far behind from its competitors. To reach the market human trials are necessary.

      Shares of iBio, Inc. (IBIO) traded up 9.30% as it gained +0.20 on Thursday. In the past 52-weeks of trading, this company’s stock has fluctuated between the low range of $0.05 and a high range of $7.45. iBio has moved up 4600.00% from its 52-weeks low and moved down -68.46% from its 52-weeks high. Looking at its profitability, its return on assets and investment is -108.70%, and -57.60%, respectively. If we turn our focus on its liquidity, its current ratio is 1.70. iBio, Inc. market capitalization has remained high, hitting $420.46 million at the time of writing.

      There are various sciences behind iBio stock. If we look at the political stories, Donald Trump is looking for a vaccine before November. Similarly, from a business point of view, billions were given to the companies for the products which are not ready for the market yet. If we turn our focus on iBio, it only claims that it has a vaccine candidate but that is still in the lab.

      It has not advanced it trial to humans which is necessary. iBio stocks soared after it revealed about the FastPharming. But it is not clear yet whether the company has a vaccine or not or it is the trick of the company to excite its stock. So, it is better to avoid the stock of iBio for the coronavirus vaccine until it starts a human trial.

      More From Stocks telegraph